Effect of JYTK on Antioxidant Status and Inflammation in Patients With Type 2 Diabetes: A Randomized Double-Blind Clinical Trial

被引:4
|
作者
Hu, Yuan [1 ]
Zhou, Xin [1 ]
Guo, Dai-Hong [1 ]
Liu, Ping [1 ]
机构
[1] Chinese Peoples Liberat Army Gen Hosp, Ctr Pharm, Fuxing Rd, Beijing 100853, Peoples R China
关键词
Type; 2; Diabetes; JYTK; Chinese Integrative Medicine; Antioxidant Status; Inflammation;
D O I
10.5812/ijem.34400
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Diabetes is a metabolic disorder caused by oxidative stress and inflammation. JianYuTangKang (JYTK), as a potential Chinese integrative medicine, is an antioxidant used in Chinese medicine with potential anti-inflammatory properties. Objectives: The present randomized clinical trial was carried out to evaluate the effects of JYTK on oxidative stress and inflammation in patients with type 2 diabetes mellitus (T2DM). Patients and Methods: The parallel, randomized, double-blinded, placebo-controlled clinical trial included 150 newly diagnosed T2DM patients receiving metformin treatment (1.5 g/day), some of whom also received JYTK (4.5 g/day) in tablet form. The control group received 4.5 g/day placebo plus 1.5 g/day metformin. Body mass index (BMI), fasting plasma glucose, urinary albumin-to-creatinine ratio, and complete blood count as well as antioxidant and inflammation indices such as tumor necrosis factor (TNF)-alpha, interleukin (IL)-6, superoxide dismutase (SOD), malonaldehyde (MDA), glutathione peroxidase (GPX), and high sensitivity C-reactive protein (hs-CRP) levels were assessed at baseline and at different time points during the treatment. Results: All 112 patients, including 59 in the treatment group (JYTK + metformin) and 52 controls (metformin only) completed the 26-week clinical trial. JYKT plus metformin treatment increased IL-6 (36.4 +/- 11.5 ng/L; P < 0.05), TNF-alpha (17.5 +/- 11.3 vs. 22.5 +/- 12.9 ng/L; P < 0.05), and MDA (1.9 +/- 0.9; P < 0.05) levels compared to the control (2.2 +/- 0.6 mM/mL), whereas total SOD level decreased (98.1 +/- 30.4 vs. 78.5 +/- 29.3 U/mL; P < 0.05). There were no changes in GPX and hs-CRP levels. There were no adverse effects associated with JYTK treatment. Conclusions: JYTK combined with metformin improves some antioxidant indices (SOD and MDA), and decreases inflammation in patients with T2DM, suggesting that it can reduce the risk of diabetic complications.
引用
收藏
页数:7
相关论文
共 50 条
  • [1] Randomized double-blind clinical trial examining the Ellagic acid effects on glycemic status, insulin resistance, antioxidant, and inflammatory factors in patients with type 2 diabetes
    Ghadimi, Mahnaz
    Foroughi, Farshad
    Hashemipour, Sima
    Rashidi Nooshabadi, Mohamadreza
    Ahmadi, Mohammad Hossein
    Ahadi Nezhad, Bahman
    Khadem Haghighian, Hossein
    PHYTOTHERAPY RESEARCH, 2021, 35 (02) : 1023 - 1032
  • [2] Effects of saffron on homocysteine, and antioxidant and inflammatory biomarkers levels in patients with type 2 diabetes mellitus: a randomized double-blind clinical trial
    Shahbazian, Hajieh
    Aleali, Armaghan Moravej
    Amani, Reza
    Namjooyan, Foroogh
    Cheraghian, Bahman
    Latifi, Seyed Mahmoud
    Bahrainian, Sara
    Ghadiri, Ataallah
    AVICENNA JOURNAL OF PHYTOMEDICINE, 2019, 9 (05) : 436 - 445
  • [3] Antioxidant effects of astaxanthin and metformin combined therapy in type 2 diabetes mellitus patients: a randomized double-blind controlled clinical trial
    Roustaei Rad, Nikoo
    Movahedian, Ahmad
    Feizi, Awat
    Aminorroaya, Ashraf
    Aarabi, Mohammad
    RESEARCH IN PHARMACEUTICAL SCIENCES, 2022, 17 (02) : 219 - 230
  • [4] Comparison of paroxetine and agomelatine in depressed type 2 diabetes mellitus patients: a double-blind, randomized, clinical trial
    Kang, Ruiying
    He, Yan
    Yan, Yuxiang
    Li, Zhiwu
    Wu, Yeqing
    Guo, Xiaojuan
    Liang, Zhigang
    Jiang, Jun
    NEUROPSYCHIATRIC DISEASE AND TREATMENT, 2015, 11 : 1307 - 1311
  • [5] Randomized Double-Blind Clinical Trial Comparaing Efficacy and Safety of Pioglitazone and Metformin in Patients with Type 2 Diabetes
    Rokeya, Begum
    Parvin, Masuma
    Bhowmik, Amrita
    Chowdhury, A. K. Azad
    DIABETES, 2011, 60 : A618 - A618
  • [6] Antioxidant effects of Carvedilol and Alluporinol in patients with diabetes type II; A randomized, double-blind placebo-controlled clinical trial
    Larijani, B
    Afshari, M
    Mojtahedi, A
    Astanehi-Asghari, F
    Hossein-Nezhad, A
    Heshmat, R
    Rezaie, A
    Zamani, MJ
    Mostafalou, S
    Abdollahi, M
    DIABETES, 2005, 54 : A513 - A513
  • [7] Effects of L-carnitine supplementation on oxidative and metabolic status in patients with type 2 diabetes mellitus: A randomized, double-blind, clinical trial
    Talenezhad, Nasir
    Rahmanian, Masoud
    Mirzavandi, Farhang
    Hosseinzadeh, Mahdieh
    Fallahzadeh, Hossein
    Reza, Javad Zavar
    Mozaffari-Khosravi, Hassan
    EUROPEAN JOURNAL OF INTEGRATIVE MEDICINE, 2020, 40
  • [8] Benefits of Curcumin Supplementation on Antioxidant Status in β-Thalassemia Major Patients: A Double-Blind Randomized Controlled Clinical Trial
    Nasseri, Esmat
    Mohammadi, Elahe
    Tamaddoni, Ahmad
    Qujeq, Durdi
    Zayeri, Farid
    Zand, Hamid
    ANNALS OF NUTRITION AND METABOLISM, 2017, 71 (3-4) : 136 - 144
  • [9] Effect of vitamin D on insulin resistance and anthropometric parameters in Type 2 diabetes; a randomized double-blind clinical trial
    Ramin Heshmat
    Ozra Tabatabaei-Malazy
    Shabnam Abbaszadeh-Ahranjani
    Samimeh Shahbazi
    Ghazal Khooshehchin
    Fathemeh Bandarian
    Bagher Larijani
    DARU Journal of Pharmaceutical Sciences, 20
  • [10] The effect of quercetin on iron overload and inflammation in β-thalassemia major patients: A double-blind randomized clinical trial
    Hezaveh, Zohreh Sajadi
    Azarkeivan, Azita
    Janani, Leila
    Hosseini, Sharieh
    Shidfar, Farzad
    COMPLEMENTARY THERAPIES IN MEDICINE, 2019, 46 : 24 - 28